Loading...
Market
What will be Kailera Therapeutics' market valuation by December 31, 2024?
3
Kailera Therapeutics•Hercules CM NewCo•Ron Renaud•Atlas Venture•Bain Capital Life Sciences•RTW Investments
Resolution / Starting Odds
Less than $1B • 25%
$1B to $2B • 25%
$2B to $3B • 25%
More than $3B • 25%
Financial news outlets and market analysis reports
Story
Kailera Therapeutics Raises $400M in Series A Financing for Obesity Treatments, Ron Renaud as CEO
Oct 1, 2024, 11:30 AM
Kailera Therapeutics, an obesity treatment developer, has raised $400 million in a Series A financing round. The startup, previously known as 'Hercules CM NewCo,' is led by CEO Ron Renaud, who has a track record of successful acquisitions. The funding round, announced on Tuesday, was backed by Atlas Venture, Bain Capital Life Sciences, and RTW Investments. This significant investment underscores the competitive nature of the obesity drug market, with Kailera Therapeutics aiming to advance its portfolio of next-generation therapies for obesity and related conditions. The company is already striking a deal for commercial manufacturing.
View original story
Similar markets
Less than $250M • 33%
$250M to $500M • 33%
More than $500M • 34%
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Above $30 • 25%
$20-$30 • 25%
$10-$20 • 25%
Below $10 • 25%
Under $1 billion • 25%
$1-2 billion • 25%
$2-3 billion • 25%
Over $3 billion • 25%
Less than $100M • 33%
$100M to $200M • 33%
More than $200M • 33%
Increase by 10% or more • 25%
Decrease by 10% or more • 25%
Remain within +/- 10% • 25%
Increase by 20% or more • 25%
Below $1 Billion • 25%
$1 Billion to $2 Billion • 25%
$2 Billion to $3 Billion • 25%
Above $3 Billion • 25%
Less than $50M • 25%
$50M to $100M • 25%
$100M to $150M • 25%
More than $150M • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Below $1.00 • 25%
$1.00 - $1.50 • 25%
$1.51 - $2.00 • 25%
Above $2.00 • 25%